NCT00537238

Pregabalin Versus Levetiracetam In Partial Seizures

A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 509 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will compare pregabalin and levetiracetam in patients with partial seizures. It will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.

Conditions

• Partial Seizures

Interventions

Type	Name	Description
DRUG	pregabalin	300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
DRUG	levetiracetam	1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects

Timeline

• Start date: 2007-10-01
• Primary completion: 2012-05-01
• Completion: 2012-05-01
• First posted: 2007-10-01
• Last updated: 2021-01-28
• Results posted: 2013-07-11

Locations

72 sites across 21 countries: Belgium, Bulgaria, Colombia, Costa Rica, Czechia, France, Germany, Greece, India, Italy, Lithuania, Mexico, Panama, Peru, Philippines, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), Venezuela